Environmental and dietary risk factors in Alzheimer’s disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that affects millions in the aging population worldwide and will affect millions more in the next 20 years. Over 90% of all cases are sporadic, with genetics playing a minor role in the etiology of AD. Therefore, it is crucial to investigate the environment and diet as primary risk factors in AD pathology. This review considers epidemiologic case control studies, and in vitro and in vivo research to investigate the potential of environmental exposure to metals, air pollution and pesticides as well as diet as risk factors for AD. In some cases, the role of genetic mutations and environmental risk is discussed. The evidence examined in this review provides a brief overview of the current literature on selected, significant risk factors in promoting amyloid-β accumulation and aggregation, thus contributing to neurodegeneration.

[1]  R. Mayeux,et al.  Caloric intake and the risk of Alzheimer disease. , 2002, Archives of neurology.

[2]  L. Fratiglioni,et al.  Risk factors for clinically diagnosed Alzheimer's disease , 1986, Neurology.

[3]  Qian-Li Xue,et al.  Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. , 2007, Archives of neurology.

[4]  H. Braak,et al.  Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. , 2003, Archives of neurology.

[5]  D. Hryhorczuk,et al.  Effect of Ozone and Aeroallergens on the Respiratory Health of Asthmatics , 2002, Archives of environmental health.

[6]  A. Hofman,et al.  Non-insulin-dependent Diabetes Mellitus (niddm) Association of Diabetes Mellitus and Dementia: the Rotterdam Study , 2022 .

[7]  C. Caltagirone,et al.  Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: from risk factors to disease modulators , 2004, Neurobiology of Aging.

[8]  J. Groves.  The bioinorganic chemistry of iron in oxygenases and supramolecular assemblies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Roberto Cappai,et al.  Metals and amyloid‐β in Alzheimer's disease , 2005, International journal of experimental pathology.

[10]  T. Bayer,et al.  Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease Published, JLR Papers in Press, October 1, 2003. DOI 10.1194/jlr.M300320-JLR200 , 2004, Journal of Lipid Research.

[11]  K. Gautschi,et al.  Failure to find a relationship between mnestic skills of octogenarians and aluminum in drinking water , 1991, International archives of occupational and environmental health.

[12]  J. Trojanowski,et al.  Aluminum modifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  Ashley I. Bush,et al.  The metallobiology of Alzheimer's disease , 2003, Trends in Neurosciences.

[14]  Johanna Kuusisto,et al.  Association between features of the insulin resistance syndrome and alzheimer's disease independently of apolipoprotein e4 phenotype: cross sectional population based study , 1997, BMJ.

[15]  P. Hof,et al.  Caloric restriction attenuates β‐amyloid neuropathology in a mouse model of Alzheimer's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  B. Kriem,et al.  Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid‐β oligomers , 2006, Journal of neurochemistry.

[17]  L. Thal,et al.  Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide , 1993, Nature.

[18]  G. Perry,et al.  Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease , 2003, Biometals.

[19]  K. Blennow,et al.  Vitamin B12-B6-Folate Treatment Improves Blood-Brain Barrier Function in Patients with Hyperhomocysteinaemia and Mild Cognitive Impairment , 2003, Dementia and Geriatric Cognitive Disorders.

[20]  S. Oyanagi,et al.  Aluminium detected in senile plaques and neurofibrillary tangles is contained in lipofuscin granules with silicon, probably as aluminosilicate , 1995, Neuroscience Letters.

[21]  J. Poirier,et al.  Cholesterol and APOE genotype interact to influence Alzheimer disease progression , 2004, Neurology.

[22]  I. Villegas,et al.  Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. , 2005, Molecular nutrition & food research.

[23]  D. Brody,et al.  Surveillance for elevated blood lead levels among children--United States, 1997-2001. , 2003, Morbidity and mortality weekly report. Surveillance summaries.

[24]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[25]  E. Porcellini,et al.  Homocysteine and folate as risk factors for dementia and Alzheimer disease. , 2005, The American journal of clinical nutrition.

[26]  Annette Peters,et al.  Translocation and potential neurological effects of fine and ultrafine particles a critical update , 2006, Particle and Fibre Toxicology.

[27]  J. Gee,et al.  Astrocytes: regulation of brain homeostasis via apolipoprotein E. , 2005, The international journal of biochemistry & cell biology.

[28]  M. Farlow,et al.  Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease Published, JLR Papers in Press, February 16, 2005. DOI 10.1194/jlr.M400486-JLR200 , 2005, Journal of Lipid Research.

[29]  J. Lambert,et al.  Is the LDL receptor-related protein involved in Alzheimer's disease? , 1999, Neurogenetics.

[30]  S. Gandy,et al.  Regulation of alzheimer beta-amyloid precursor trafficking and metabolism. , 2000, Advances in experimental medicine and biology.

[31]  C. Czech,et al.  Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms , 2000, Progress in Neurobiology.

[32]  J. Vaupel,et al.  Alzheimer's disease in twins , 1996, The Lancet.

[33]  W. Niklowitz,et al.  Neurofibrillary changes following childhood lead encephalopathy. , 1975, Journal of neuropathology and experimental neurology.

[34]  W. Lukiw,et al.  WOULD DECREASED ALUMINIUM INGESTION REDUCED THE INCIDENCE OF ALZHEIMER'S DISEASE ? , 1991 .

[35]  N. Janel,et al.  Plasma homocysteine levels are not increased in murine models of Alzheimer's disease , 2005, Neuroscience Research.

[36]  Takashi Morihara,et al.  Dietary n‐3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease , 2005, The European journal of neuroscience.

[37]  Physostigmine: improvement of long-term memory processes in normal humans. , 1979, Science.

[38]  D. Shen,et al.  Past adult lead exposure is linked to neurodegeneration measured by brain MRI , 2006, Neurology.

[39]  G. Hatch,et al.  Evidence that exposure of particulate air pollutants to human and rat alveolar macrophages leads to differential oxidative response. , 1997, Biochemical and biophysical research communications.

[40]  Kenneth Rockwood,et al.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.

[41]  Yung-Hyun Choi,et al.  Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in beta-amyloid-treated C6 glioma cells. , 2006, International journal of molecular medicine.

[42]  H. Tanila,et al.  Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice , 2006, Neurobiology of Disease.

[43]  D. Butterfield,et al.  Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. , 2006, Journal of Alzheimer's disease : JAD.

[44]  Roger L. Black,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .

[45]  Julie A Schneider,et al.  Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[46]  N. Cairns,et al.  Amyloid precursor protein mRNA levels in Alzheimer's disease brain. , 2004, Brain research. Molecular brain research.

[47]  P. Solomon,et al.  A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. , 1994, JAMA.

[48]  Matthew P. Frosch,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Steve Meaney,et al.  Brain Cholesterol: Long Secret Life Behind a Barrier , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[50]  R. Basha,et al.  The Fetal Basis of Amyloidogenesis: Exposure to Lead and Latent Overexpression of Amyloid Precursor Protein and β-Amyloid in the Aging Brain , 2005, The Journal of Neuroscience.

[51]  A. Hofman,et al.  Frequency and distribution of Alzheimer's disease in Europe: A collaborative study of 1980–1990 prevalence findings , 1991, Annals of neurology.

[52]  B. Lawlor,et al.  Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case–control study , 2003, British Journal of Nutrition.

[53]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[54]  B. Cheung,et al.  Intron 2 (T/C) CYP46 Polymorphism Is Associated with Alzheimer’s Disease in Chinese Patients , 2006, Dementia and Geriatric Cognitive Disorders.

[55]  Peter Davies,et al.  Resveratrol Promotes Clearance of Alzheimer's Disease Amyloid-β Peptides* , 2005, Journal of Biological Chemistry.

[56]  D. Bennett,et al.  Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive decline , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[57]  A. Karczmar.  Invited Review Anticholinesterases: dramatic aspects of their use and misuse , 1998, Neurochemistry International.

[58]  Charles N Serhan,et al.  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. , 2005, The Journal of clinical investigation.

[59]  N. Zawia,et al.  Lead-induced developmental perturbations in hippocampal Sp1 DNA-binding are prevented by zinc supplementation: in vivo evidence for Pb and Zn competition , 2003, International Journal of Developmental Neuroscience.

[60]  W. Kreyling,et al.  Translocation of Inhaled Ultrafine Particles to the Brain , 2004, Inhalation toxicology.

[61]  P. Solomon,et al.  Neurochemical characteristics of aluminum-induced neurofibrillary degeneration in rabbits , 1987, Neuroscience.

[62]  F. Guengerich,et al.  Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. , 2001, Chemical research in toxicology.

[63]  Yaakov Stern,et al.  Mediterranean diet, Alzheimer disease, and vascular mediation. , 2006, Archives of neurology.

[64]  R. Palmiter,et al.  Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Kathleen A. Boyle,et al.  Amyloid-β peptide binds with heme to form a peroxidase: Relationship to the cytopathologies of Alzheimer’s disease , 2006 .

[66]  D. Dockery,et al.  Fungus spores, air pollutants, and other determinants of peak expiratory flow rate in children. , 1996, American journal of epidemiology.

[67]  E M Wijsman,et al.  Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease , 1995, Neurology.

[68]  V. Sánchez-Margalet,et al.  Homocysteine thiolactone inhibits insulin signaling, and glutathione has a protective effect. , 2001, Journal of molecular endocrinology.

[69]  Rhoda Au,et al.  Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. , 2006, Archives of neurology.

[70]  M. Schrag,et al.  Deposition of iron and β‐amyloid plaques is associated with cortical cellular damage in rabbits fed with long‐term cholesterol‐enriched diets , 2006, Journal of neurochemistry.

[71]  C. Schweiger.  [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[72]  E. Seifritz,et al.  Red Wine Ingredient Resveratrol Protects from β-Amyloid Neurotoxicity , 2003, Gerontology.

[73]  W. Pierson,et al.  Air pollutants and the respiratory system: toxicity and pharmacologic interventions. , 1991, Journal of toxicology. Clinical toxicology.

[74]  S. Kira,et al.  Lead content of brain tissue in diffuse neurofibrillary tangles with calcification (DNTC): the possibility of lead neurotoxicity , 2001, Neuroreport.

[75]  H. Tohgi,et al.  Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease , 1999, Neuroscience Letters.

[76]  G. Bratton,et al.  Differential ability of astroglia and neuronal cells to accumulate lead: dependence on cell type and on degree of differentiation. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[77]  P. Falkai,et al.  Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease , 2006, Experimental Gerontology.

[78]  D. Selkoe,et al.  Translating cell biology into therapeutic advances in Alzheimer's disease , 1999, Nature.

[79]  J. Selhub,et al.  Vitamin B-6 deficiency vs folate deficiency: comparison of responses to methionine loading in rats. , 1994, The American journal of clinical nutrition.

[80]  Harvey S. Levin,et al.  Effects of physostigmine and lecithin on memory in Alzheimer disease , 1979, Annals of neurology.

[81]  James S. Brown,et al.  Ultrafine particle deposition and clearance in the healthy and obstructed lung. , 2002, American journal of respiratory and critical care medicine.

[82]  B. Greenberg,et al.  A new A4 amyloid mRNA contains a domain homologous to serine protease inhibitors , 1988 .

[83]  S. Gandy,et al.  Regulation of Alzheimer -amyloid precursor trafficking and metabolism 1 1 Portions of this review h , 2000 .

[84]  H. Feldman,et al.  Functional, Cognitive and Behavioral Effects of Donepezil in Patients with Moderate Alzheimer's Disease , 2002, Current medical research and opinion.

[85]  A. Besarab,et al.  Intracranial calcification in adults with chronic lead exposure. , 1985, AJR. American journal of roentgenology.

[86]  Mei-Hua Huang,et al.  Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. , 2005, The American journal of medicine.

[87]  Sudha Seshadri,et al.  Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease , 2002 .

[88]  W. D. Ehmann,et al.  Laser microprobe analysis of brain aluminum in Alzheimer' disease , 1993, Annals of neurology.

[89]  B. Greenberg,et al.  A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors , 1988, Nature.

[90]  B. Borroni,et al.  APOE genotype and cholesterol levels in lewy body dementia and Alzheimer disease: investigating genotype-phenotype effect on disease risk. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[91]  H. Tohgi,et al.  Remarkable increase in the concentration of 8‐hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease , 2002, Journal of neuroscience research.

[92]  D. Bennett,et al.  Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.

[93]  D. Sparks,et al.  Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[94]  M. Cankurtaran,et al.  Vitamin B12, folate, homocysteine and dementia: are they really related? , 2005, Archives of gerontology and geriatrics.

[95]  Alan L. Miller,et al.  Methionine and Homocysteine Metabolism and the Nutritional Prevention of Certain Birth Defects and Complications of Pregnancy , 1996 .

[96]  H. Staehelin,et al.  Micronutrients and Alzheimer's disease , 2005, Proceedings of the Nutrition Society.

[97]  Z. Ungvari,et al.  Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen. , 2006, Current medicinal chemistry.

[98]  J. Dartigues,et al.  Neurodegenerative diseases and exposure to pesticides in the elderly. , 2003, American journal of epidemiology.

[99]  D. Selkoe,et al.  Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments , 1992, Nature.

[100]  E. Leof,et al.  The FASEB Journal • Research Communication Imatinib mesylate blocks a non-Smad TGF- � pathway and reduces renal fibrogenesis in vivo , 2022 .

[101]  V. Haroutunian,et al.  Elevated cortical zinc in Alzheimer disease , 2006, Neurology.

[102]  L. Wahlund,et al.  The Relation between Homocysteine Levels and Development of Alzheimer’s Disease in Mild Cognitive Impairment Patients , 2005, Dementia and Geriatric Cognitive Disorders.

[103]  Xudong Huang,et al.  Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. , 2008, Journal of neurochemistry.

[104]  M. Kamboh,et al.  Molecular Genetics of Late‐Onset Alzheimer's Disease , 2004, Annals of human genetics.

[105]  R. Ransohoff,et al.  The expression and function of chemokines involved in CNS inflammation. , 2006, Trends in pharmacological sciences.

[106]  Jun Wang,et al.  Moderate consumption of Cabernet Sauvignon attenuates A� neuropathology in a mouse model of Alzheimer's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[107]  Priya Anand,et al.  Oxidative damage following chronic aluminium exposure in adult and pup rat brains. , 2005, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[108]  Jun Wang,et al.  Neuronal SIRT1 Activation as a Novel Mechanism Underlying the Prevention of Alzheimer Disease Amyloid Neuropathology by Calorie Restriction* , 2006, Journal of Biological Chemistry.

[109]  L. Villa-komaroff,et al.  Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease , 1988, Nature.

[110]  Gastone G. Celesia,et al.  A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .

[111]  E. D. Harris,et al.  Lead targets GRP78, a molecular chaperone, in C6 rat glioma cells. , 2000, Toxicology and applied pharmacology.

[112]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[113]  Steffen Loft,et al.  Oxidative stress-induced DNA damage by particulate air pollution. , 2005, Mutation research.

[114]  P. Panegyres.  The amyloid precursor protein gene: a neuropeptide gene with diverse functions in the central nervous system , 1997, Neuropeptides.

[115]  David E Newby,et al.  Do inhaled carbon nanoparticles translocate directly into the circulation in humans? , 2006, American journal of respiratory and critical care medicine.

[116]  T. Tokuda,et al.  Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans , 2003, Neuroscience Letters.

[117]  B. Gordon,et al.  Past adult lead exposure is associated with longitudinal decline in cognitive function , 2000, Neurology.

[118]  F. Panza,et al.  Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[119]  D. Barker.  Fetal programming of coronary heart disease , 2002, Trends in Endocrinology & Metabolism.

[120]  P S Barry,et al.  Lead concentrations in human tissues , 1970, British journal of industrial medicine.

[121]  M. Boeniger,et al.  Neurodegenerative diseases: occupational occurrence and potential risk factors, 1982 through 1991. , 1996, American journal of public health.

[122]  D. Butterfield,et al.  Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: An approach to understand pathological and biochemical alterations in AD , 2006, Neurobiology of Aging.

[123]  J. Poirier,et al.  The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease , 1998, Brain Research Reviews.

[124]  L. Fratiglioni,et al.  Complete ascertainment of dementia in the Swedish Twin Registry: the HARMONY study , 2005, Neurobiology of Aging.

[125]  W. D. Ehmann,et al.  Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress , 1996, Journal of the Neurological Sciences.

[126]  W. Porter,et al.  Behavioral and neurochemical changes associated with chronic exposure to low-level concentration of pesticide mixtures. , 1990, Journal of toxicology and environmental health.

[127]  C. Behl,et al.  Testosterone stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen-activated protein kinase pathway , 2000, Neuroscience Letters.

[128]  A. Leviton,et al.  Deficits in psychologic and classroom performance of children with elevated dentine lead levels. , 1979, The New England journal of medicine.

[129]  Xianlin Han,et al.  ABCA1 Is Required for Normal Central Nervous System ApoE Levels and for Lipidation of Astrocyte-secreted apoE* , 2004, Journal of Biological Chemistry.

[130]  J. Growdon,et al.  Association of homocysteine with plasma amyloid β protein in aging and neurodegenerative disease , 2005, Neurology.

[131]  F. Panza,et al.  Lipid metabolism in cognitive decline and dementia , 2006, Brain Research Reviews.

[132]  H. Morita,et al.  Plasma levels of amyloid β proteins did not differ between subjects taking statins and those not taking statins , 2001, Annals of neurology.

[133]  A. Karczmar,et al.  Anticholinesterase Agents. , 1963, Science.

[134]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[135]  M. Pappolla,et al.  Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid β peptide levels , 2006, Neurobiology of Disease.

[136]  D. Alkon,et al.  Oxidation of Cholesterol by Amyloid Precursor Protein and β-Amyloid Peptide* , 2005, Journal of Biological Chemistry.

[137]  H Frauenfelder,et al.  The role of structure, energy landscape, dynamics, and allostery in the enzymatic function of myoglobin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[138]  R. Maronpot,et al.  Brain Inflammation and Alzheimer's-Like Pathology in Individuals Exposed to Severe Air Pollution , 2004, Toxicologic pathology.

[139]  S. Melov,et al.  Alzheimer disease β-amyloid activity mimics cholesterol oxidase , 2005 .

[140]  B. Teter,et al.  Insulin-Degrading Enzyme as a Downstream Target of Insulin Receptor Signaling Cascade: Implications for Alzheimer's Disease Intervention , 2004, The Journal of Neuroscience.

[141]  A. Ludolph,et al.  Experimental and clinical neurotoxicology , 1980 .

[142]  J. Loscalzo,et al.  Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. , 2005, Blood.

[143]  Xudong Huang,et al.  Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). , 2002, The Journal of biological chemistry.

[144]  W. Lukiw,et al.  Would decreased aluminum ingestion reduce the incidence of Alzheimer's disease? , 1991, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[145]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[146]  R. Canfield,et al.  Intellectual Impairment in Children with Blood Lead Concentrations below 10 μ g per Deciliter , 2003 .

[147]  T. Anekonda.  Resveratrol—A boon for treating Alzheimer's disease? , 2006, Brain Research Reviews.

[148]  T. Montine,et al.  Cerebrospinal fluid F2‐isoprostane levels are increased in Alzheimer's disease , 1998, Annals of neurology.

[149]  P. Fraser,et al.  Metallothionein III is reduced in Alzheimer’s disease , 2001, Brain Research.

[150]  R. Maronpot,et al.  DNA Damage in Nasal and Brain Tissues of Canines Exposed to Air Pollutants Is Associated with Evidence of Chronic Brain Inflammation and Neurodegeneration , 2003, Toxicologic pathology.

[151]  H. Wiśniewski,et al.  EXPERIMENTAL PRODUCTION OF NEUROFIBRILLARY DEGENERATION: 1. LIGHT MICROSCOPIC OBSERVATIONS , 1965, Journal of neuropathology and experimental neurology.

[152]  L. Fleming,et al.  Parkinson's disease and brain levels of organochlorine pesticides , 1994, Annals of neurology.

[153]  Oliver Wirths,et al.  Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice , 2001, Neuroscience Letters.

[154]  H. Lashuel,et al.  Lead ( Pb ) exposure and its effect on APP proteolysis and A β aggregation , 2005 .

[155]  I. Fortier,et al.  Environmental pesticide exposure as a risk factor for Alzheimer's disease: a case-control study. , 2001, Environmental research.

[156]  S. Singer,et al.  Aluminum-induced neuropathology: transient changes in microtubule-associated proteins. , 1996, Neurotoxicology and teratology.

[157]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[158]  G. Nisticó,et al.  Evidence that paraquat is able to cross the blood-brain barrier to a different extent in rats of various age. , 1991, Functional neurology.

[159]  H. Feldman,et al.  Causes of Alzheimer's disease. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[160]  D. Selkoe,et al.  The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. , 2000, Biochemistry.

[161]  Lars-Olof Wahlund,et al.  Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. , 2006, Archives of neurology.

[162]  N. Bresolin,et al.  Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease , 2006, Neurobiology of Aging.

[163]  Ze Yang,et al.  Association of MTHFR gene polymorphism C677T with susceptibility to late-onset alzheimer’s disease , 2007, Journal of Molecular Neuroscience.

[164]  C. Exley.  A molecular mechanism of aluminium-induced Alzheimer's disease? , 1999, Journal of inorganic biochemistry.

[165]  R. Canfield,et al.  Intellectual Impairment in Children with Blood Lead Concentrations below 10 μg per Deciliter , 2003 .

[166]  N. Greig,et al.  Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. , 2004, Current pharmaceutical design.

[167]  D. Butterfield,et al.  Protective effect of D609 against amyloid‐beta1–42‐induced oxidative modification of neuronal proteins: Redox proteomics study , 2006, Journal of neuroscience research.